YARW — YARROW BIOSCIENCE Share News
0.000.00%
Last trade - 00:00- $181.86m
- $158.94m
- $0.57m
U.S. STOCKS ON THE MOVE-Mega-cap growth stocks, U.S. restaurants
U.S. STOCKS ON THE MOVE-Retail stocks, payment firms, travel stocks
U.S. STOCKS ON THE MOVE-Twitter, Nikola, Tesla, Xeris Biopharma
Vyne Therapeutics slumps after eczema drug fails mid-stage trial
Brief: Vyne Therapeutics Announces Results From Its Phase 2A Trial Of Fmx114 For The Treatment Of Mild-To-Moderate Atopic Dermatitis
Vyne Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Vyne Therapeutics Completes Enrollment In Phase 2A Trial Of FMX114 For Treatment Of Mild-To-Moderate Atopic Dermatitis
Vyne Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Vyne Therapeutics Reports Net Income For Three Months Ended March 31, 2022 Was $4.7 Mln
Vyne Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Vyne Therapeutics jumps after positive data on eczema treatment
Brief: Vyne Reports Positive Preclinical Data For Intra-Articular Injection Of Pan-Bet Inhibitor, Vyn201, In An In Vivo Model Of Rheumatoid Arthritis
Brief: Vyne Therapeutics Reports Qtrly Loss Per Share 22 Cents
Vyne Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Vyne Therapeutics Says Entered Into A Purchase Agreement With Lincoln Park
Brief: Vyne Therapeutics Says Expects To Report Phase 2A Fmx114 Study Top Line Results In Q2 Of 2022
Brief: VYNE Reports Positive Preclinical Data For Lead BET Inhibitor, VYN201, In Human Skin Model Of Vitiligo
Vyne Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Vyne Therapeutics Announces Phase 1B Data For Treatment Of Mild-To-Moderate Atopic Dermatitis